ArticleFrontiers in immunology2026
Glycosaminoglycan binding to soluble CX3CL1 impacts monocyte migration
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In addition to providing shear-resistant cell-cell adhesion in its natural membrane-bound form, the soluble variant of CX3CL1 (or fractalkine) promotes strong cell migration through signaling via its unique G-protein-coupled receptor CX3CR1 on monocytes, macrophages, T-cells, and NK-cells. To induce cell migration, most chemokines benefit from their interaction with the heterogenous group of glycosaminoglycans (GAGs), which act as coreceptors in chemotactic processes. While the interaction of many chemokines with their GAG counterparts has been investigated in detail, the potential interaction of CX3CL1 and GAGs has not yet received sufficient attention. Results: Here, we show that the bioactive N-terminal, soluble chemokine domain of CX3CL1 (cdCX3CL1) binds to heparan sulfate (HS) as well as to dermatan sulfate (DS or CS-B), exhibiting Kd-values in the mid nanomolar range. Moreover, the removal of monocyte-surface HS reduced cdCX3CL1-induced cell migration, thereby strongly indicating a potential biological relevance of CX3CL1 binding to GAGs. Interaction studies taking into account the extracellular receptor-peptide of CX3CR1 showed that, in addition to binding CX3CL1, CX3CR1 was found to bind to HS as well. Cross-linking cdCX3CL1 and the CX3CR1 peptide led to a ten-fold higher HS binding affinity compared to the isolated proteins. Discussion: These findings further strengthen the assumption of an extended interaction network, in which GPCR, chemokine, and GAGs affect each other simultaneously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.